|
Based on the Phase II data, Imbria Pharmaceuticals’ inerafaxstat could complement existing treatments rather than replace them.
|
 |
|
Non-profit organisations provide an alternative to rescue stalled orphan drugs for biotechs struggling against a lethargic investment climate.
|
|
|
Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease caused by RSV.
|
|
|
Completed biopharma IPOs that raised more than $100 million saw a twofold increase during the year.
|
|
|
The move has been triggered by reports of overpricing, but there are warnings that an expansion of the IRP scheme may be a step too far.
|
|
|
Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper hand.
|
|
|
Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.
|
|
